How a longtime Peninsula biotech company's stomach cancer drug moved closer to the finish line
Results this month from the company's mid-stage clinical trial sent its stock soaring and helped it raise $174 million. But it took nine years, layoffs, CEO changes and serendipity to get there.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Gastric (Stomach) Cancer | Health Management